Litigation Details for ABRAXIS BIOSCIENCE, LLC v. HBT LABS, INC. (D.N.J. 2018)
✉ Email this page to a colleague
ABRAXIS BIOSCIENCE, LLC v. HBT LABS, INC. (D.N.J. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-12-16 |
| Court | District Court, D. New Jersey | Date Terminated | 2019-02-06 |
| Cause | 15:1126 Patent Infringement | Assigned To | John Michael Vazquez |
| Jury Demand | None | Referred To | Mark Falk |
| Parties | CELGENE CORPORATION | ||
| Patents | 7,758,891; 7,820,788; 7,923,536; 8,034,375; 8,138,229; 8,268,348; 8,314,156; 8,853,260; 9,101,543; 9,393,318; 9,511,046; 9,597,409 | ||
| Attorneys | WILLIAM C. BATON | ||
| Firms | Saul Ewing Arnstein & Lehr LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ABRAXIS BIOSCIENCE, LLC v. HBT LABS, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Biologic Drugs cited in ABRAXIS BIOSCIENCE, LLC v. HBT LABS, INC.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for ABRAXIS BIOSCIENCE, LLC v. HBT LABS, INC. (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-12-16 | 1 | States Patent Nos. 7,758,891 (“’891 patent”), 7,820,788 (“’788 patent”), 7,923,536 (“’536 patent”), 8,…(“’348 patent”), 8,314,156 (“’156 patent”), 8,853,260 (“’260 patent”), 9,101,543 (“’543 patent”), 9,393,318…,393,318 (“’318 patent”), 9,511,046 (“’046 patent”), and 9,597,409 (“’409 patent”), all owned by Abraxis… 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C…8,034,375 (“’375 patent”), 8,138,229 (“’229 patent”), Case 2:18-cv-17304-JMV-MF Document 1 Filed 12/17 | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
